Karyopharm Therapeutics Inc (NASDAQ:KPTI) CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $10.09, for a total value of $100,900.00. Following the completion of the transaction, the chief executive officer now owns 522,143 shares of the company’s stock, valued at $5,268,422.87. The transaction was disclosed in a filing with the SEC, which is available at this link.

Michael Kauffman also recently made the following trade(s):

  • On Monday, December 18th, Michael Kauffman sold 10,000 shares of Karyopharm Therapeutics stock. The stock was sold at an average price of $9.16, for a total value of $91,600.00.

Shares of Karyopharm Therapeutics Inc (KPTI) opened at $10.78 on Wednesday. Karyopharm Therapeutics Inc has a 52 week low of $7.48 and a 52 week high of $14.63. The firm has a market capitalization of $508.61, a PE ratio of -4.05 and a beta of 4.08.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities analysts anticipate that Karyopharm Therapeutics Inc will post -2.58 earnings per share for the current year.

A number of research firms have recently issued reports on KPTI. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, October 13th. Robert W. Baird reiterated a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the stock a “buy” rating in a report on Tuesday, December 12th. BidaskClub raised Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Finally, HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $17.33.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KPTI. Voya Investment Management LLC raised its position in Karyopharm Therapeutics by 42.1% during the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after purchasing an additional 4,444 shares during the last quarter. Tudor Investment Corp ET AL bought a new position in Karyopharm Therapeutics during the 2nd quarter valued at approximately $136,000. The Manufacturers Life Insurance Company raised its position in Karyopharm Therapeutics by 26.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after purchasing an additional 5,586 shares during the last quarter. ProShare Advisors LLC raised its position in Karyopharm Therapeutics by 8.0% during the 2nd quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares during the last quarter. Finally, New York State Common Retirement Fund raised its position in Karyopharm Therapeutics by 33.6% during the 2nd quarter. New York State Common Retirement Fund now owns 28,200 shares of the company’s stock valued at $255,000 after purchasing an additional 7,099 shares during the last quarter. 60.89% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Karyopharm Therapeutics Inc (KPTI) CEO Sells $100,900.00 in Stock” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.watchlistnews.com/karyopharm-therapeutics-inc-kpti-ceo-sells-100900-00-in-stock/1820954.html.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.